Nektar Therapeutics (NKTR)
0.718
-0.03
(-3.38%)
USD |
NASDAQ |
Mar 24, 16:00
0.7439
+0.03
(+3.61%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 135.87M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -87.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.460 |
| Price to Book Value | 0.3706 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.47% |
News
Headline
Wire
Time (ET)
PR Newswire
03/11 19:00
MT Newswires
03/06 09:01
PR Newswire
02/28 17:15
MT Newswires
02/27 10:20
Yahoo
02/24 14:21
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -0.32 | -0.43 | 25.05% | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.31 | -0.44 | 28.87% | |
| 11/03/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.85 | -1.02 | 16.38% | |
| 08/04/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.49 | -0.67 | 26.60% |
*Estimated Date/Time
Earnings
Profile
Edit
| Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World. |
| URL | https://www.nektar.com |
| Investor Relations URL | https://ir.nektar.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 92.06M |
| Total Expenses (TTM) | 332.29M |
| Net Income (TTM) | -368.20M |
| Total Assets (Quarterly) | 710.60M |
| Total Liabilities (Quarterly) | 343.96M |
| Shareholders Equity (Quarterly) | 366.64M |
| Cash from Operations (TTM) | -304.01M |
| Cash from Investing (TTM) | 365.84M |
| Cash from Financing (TTM) | 1.508M |
Ratings
Profile
Edit
| Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World. |
| URL | https://www.nektar.com |
| Investor Relations URL | https://ir.nektar.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NKTR Tweets |